1
|
Matsuura S, Nagata S, Shibazaki K, Uchida R, Imai Y, Shibata S, Morita H. Increased skeletal muscle mass index was involved in glycemic efficacy following diabetes treatment, and changes in fat mass index correlated with the changes in the lipid ratio in type 2 diabetes. J Diabetes Complications 2024; 38:108717. [PMID: 38422562 DOI: 10.1016/j.jdiacomp.2024.108717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 11/01/2023] [Accepted: 02/26/2024] [Indexed: 03/02/2024]
Abstract
AIM This study aimed to investigate the association between changes in body composition, glycated hemoglobin, and lipid ratio during the treatment of patients with type 2 diabetes mellitus (T2DM). METHODS This retrospective analysis used data from outpatients with T2DM who had confirmed body composition and measured laboratories at administration and after treatment. The baseline characteristics and prescribed treatment were collected. The total cholesterol/high-density lipoprotein cholesterol (HDL) ratio, low-density lipoprotein cholesterol (LDL)/HDL ratio, and triglyceride-glucose (TyG) index were also calculated. RESULTS A total of 207 patients (mean patient age, 62.0 ± 13.7 years; 68.1 % males) were enrolled. Fat mass index (FMI) changes correlated with the changes in the lipid ratio, whereas skeletal muscle mass index (SMI) changes inversely correlated with glycated hemoglobin (HbA1c) changes. Multiple regression analysis showed that changes in LDL/HDL and TyG correlated with FMI changes (t = 2.388, p = 0.017, t = 2.022, p = 0.044). Conversely, HbA1c changes correlated with SMI changes (t = -2.552, p = 0.011). CONCLUSION In patients with T2DM, increased SMI was involved in glycemic efficacy, and FMI changes were associated with LDL/HDL and TyG.
Collapse
Affiliation(s)
- Shun Matsuura
- Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan; Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan.
| | - Soichiro Nagata
- Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan
| | - Koji Shibazaki
- Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan
| | - Reiko Uchida
- Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan
| | - Yukiko Imai
- Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan
| | - Shoko Shibata
- Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan
| | - Hiroshi Morita
- Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan
| |
Collapse
|
2
|
Matsuura S, Serizawa S, Yamashita R, Morikawa K, Ito Y, Hiramatsu T, Mochizuki E, Tanaka K, Akiyama N, Tsukui M, Koshimizu N, Kosugi T. The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer. Ann Med 2023; 55:2196089. [PMID: 37043179 PMCID: PMC10101664 DOI: 10.1080/07853890.2023.2196089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/13/2023] Open
Abstract
BACKGROUND Adjuvant durvalumab after chemoradiation has become the standard of care for patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before durvalumab for patients with stage III NSCLC showed predictive and prognostic effects remains unknown. METHODS This is a retrospective study in the Fujieda Municipal General Hospital between October 2018 and March 2022. We assessed the predictive value of the Prognostic Nutritional Index (PNI) in stage III non-small cell lung cancer (NSCLC) patients treated with durvalumab after chemoradiation. RESULTS After applying the inclusion and exclusion criteria, the study included 56 patients for further analysis. The median follow-up period was 17.6 months (range, 3.0-45.4 months). According to receiver operating characteristic curve results, the PNI cutoff value to predict overall survival (OS) was 37.9, with sensitivity and specificity at 67.9% and 67.9%. Accordingly, the patients were divided into low- and high-PNI groups. Patients with the low-PNI group had a significantly shorter progression-free survival compared to the high-PNI group (median, 9.1 vs. 21.3 months, p = 0.032). OS was also shorter in the low-PNI group (median, 19.0 months vs. not reached, p < 0.001). In the multivariate Cox hazards regression analyses, the high-PNI was an independent prognostic factor for OS (hazard ratio, 0.187; 95% confidence interval, 0.046-0.760; p = 0.019). It seems that PNI could be used as a predictor for OS in patients with stage III NSCLC treated with durvalumab after chemoradiation.KEY MESSAGESInadequate immunocompetence and nutritional status after chemoradiation therapy may result in poor antitumor efficacy of ICIs.Pretreatment immune and nutritional assessment using PNI could be considered an independent predictor for the survival of stage III NSCLC patients treated with durvalumab after chemoradiation therapy.
Collapse
Affiliation(s)
- Shun Matsuura
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Sayaka Serizawa
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Ryoma Yamashita
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Keisuke Morikawa
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Yutaro Ito
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Toshiya Hiramatsu
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Eisuke Mochizuki
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Kazuki Tanaka
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Norimichi Akiyama
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Masaru Tsukui
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Naoki Koshimizu
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Takashi Kosugi
- Department of Radiation Oncology, Fujieda Municipal General Hospital, Fujieda, Japan
| |
Collapse
|
3
|
Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Ikeda M, Matsuda H, Inami N, Kaida Y, Funayama S, Ichikawa S, Goshima S, Suda T. Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study. J Immunother Cancer 2023; 11:e007056. [PMID: 37500182 PMCID: PMC10387737 DOI: 10.1136/jitc-2023-007056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/10/2023] [Indexed: 07/29/2023] Open
Abstract
BACKGROUND There has been no prospective trial for treatment of immune-related pneumonitis (irP) occurred after immune checkpoint inhibitors (ICIs). METHODS In this single-arm phase II study, patients with cancer with grade ≥2 irP received oral prednisolone (1 mg/kg/day), tapered over 6 weeks. The primary endpoint was a pneumonitis control rate at 6 weeks from the start of the study treatment, defined as complete disappearance or partial improvement of irP in high-resolution CT of the chest. RESULTS Among 57 patients enrolled, 56 were included in the final analysis. The most frequent cause of irP was single ICI therapy (51.8%), followed by combination with chemotherapy plus ICI (39.3%). Thirty-five (62.5%) patients had grade 2 irP and 21 (37.5%) had grade ≥3. Fifty-one (91.1%) patients completed the study treatment while 5 discontinued the study treatment because of relapse of irP (n=1), death from cancer (n=1), occurrence of immune-related hepatitis (n=1), extension of the treatment duration more than 6 weeks (n=1), and attending physician's decision (n=1). Six weeks after the start of the study treatment, 16 (28.5%) patients demonstrated complete recovery from irP, 35 (62.5%) had a partial improvement in irP, 1 (1.8%) had a relapse of irP, and 4 (7.1%) were not evaluable. The pneumonitis control rate at 6 weeks was 91.1% (95% CI, 80.7% to 96.1%). Twelve weeks after the start of the study treatment, 5 (8.9%), 27 (48.2%), and 15 (26.8%) patients demonstrated complete recovery, partial improvement, and relapse, respectively, and 9 (16.1%) were not evaluable. The pneumonitis control rate at 12 weeks was 57.1% (95% CI, 44.1% to 69.2%). During the observation period, 18 (32.1%) patients experienced a relapse of irP, and of those, 17 received re-treatment with corticosteroids. Grade ≥3 adverse events occurred in 10 (17.9%) patients, in which hyperglycemia was most frequent (n=6). There was no treatment-related death. CONCLUSIONS In this first prospective study for irP, prednisolone at 1 mg/kg/day, tapered over 6 weeks, demonstrated a promising clinical benefit and manageable toxicity, suggesting a potential treatment option for irP. TRIAL REGISTRATION NUMBER jRCT: 1041190029.
Collapse
Affiliation(s)
- Masato Karayama
- Department of Chemotherapy, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Naoki Inui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yusuke Inoue
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hideki Yasui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hironao Hozumi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yuzo Suzuki
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kazuki Furuhashi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Tomoyuki Fujisawa
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Noriyuki Enomoto
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kazuhiro Asada
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - Tomohiro Uto
- Department of Respiratory Medicine, Iwata City Hospital, Iwata, Japan
| | - Masato Fujii
- Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
| | - Takashi Matsui
- Department of Respiratory Medicine, Seirei Mikatahara Hospital, Hamamatsu, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Dai Hashimoto
- Department of Respiratory Medicine, Seirei Hamamatsu Hospital, Hamamatsu, Japan
| | - Mikio Toyoshima
- Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan
| | - Masaki Ikeda
- Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
| | - Hiroyuki Matsuda
- Department of Respiratory Medicine, Shizuoka Red Cross Hospital, Shizuoka, Japan
| | - Nao Inami
- Department of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan
| | - Yusuke Kaida
- Department of Respiratory Medicine, Enshu Byoin, Hamamatsu, Japan
| | - Satoshi Funayama
- Department of Radiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Shintaro Ichikawa
- Department of Radiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Satoshi Goshima
- Department of Radiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
4
|
Inoue Y, Inui N, Karayama M, Asada K, Fujii M, Matsuura S, Uto T, Hashimoto D, Matsui T, Ikeda M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Suda T. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy. Cancer Immunol Immunother 2023:10.1007/s00262-023-03453-z. [PMID: 37099186 DOI: 10.1007/s00262-023-03453-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Accepted: 04/16/2023] [Indexed: 04/27/2023]
Abstract
Whether circulating levels of specific cytokines at baseline link with treatment efficacy of immune checkpoint blockade (ICB) therapy in patients with non-small cell lung cancer remains unknown. In this study, serum samples were collected in two independent, prospective, multicenter cohorts before the initiation of ICB. Twenty cytokines were quantified, and cutoff values were determined by receiver operating characteristic analyses to predict non-durable benefit. The associations of each dichotomized cytokine status with survival outcomes were assessed. In the discovery cohort (atezolizumab cohort; N = 81), there were significant differences in progression-free survival (PFS) in accordance with the levels of IL-6 (log-rank test, P = 0.0014), IL-15 (P = 0.00011), MCP-1 (P = 0.013), MIP-1β (P = 0.0035), and PDGF-AB/BB (P = 0.016). Of these, levels of IL-6 and IL-15 were also significantly prognostic in the validation cohort (nivolumab cohort, N = 139) for PFS (log-rank test, P = 0.011 for IL-6 and P = 0.00065 for IL-15) and overall survival (OS; P = 3.3E-6 for IL-6 and P = 0.0022 for IL-15). In the merged cohort, IL-6high and IL-15high were identified as independent unfavorable prognostic factors for PFS and OS. The combined IL-6 and IL-15 status stratified patient survival outcomes into three distinct groups for both PFS and OS. In conclusion, combined assessment of circulating IL-6 and IL-15 levels at baseline provides valuable information to stratify the clinical outcome of patients with non-small cell lung cancer treated with ICB. Further studies are required to decipher the mechanistic basis of this finding.
Collapse
Affiliation(s)
- Yusuke Inoue
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan.
| | - Naoki Inui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
- Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| | - Masato Karayama
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
- Department of Chemotherapy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| | - Kazuhiro Asada
- Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-Ando, Shizuoka, 420-8527, Japan
| | - Masato Fujii
- Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, 10-93 Otemachi, Shizuoka, 420-8630, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, 426-8677, Japan
| | - Tomohiro Uto
- Department of Respiratory Medicine, Iwata City Hospital, 512-3 Ohkubo, Iwata, 438-8550, Japan
| | - Dai Hashimoto
- Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Naka-Ku, Hamamatsu, 430-8558, Japan
| | - Takashi Matsui
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, 3453 Mikatahara, Kita-Ku, Hamamatsu, 433-8558, Japan
| | - Masaki Ikeda
- Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, 1-1-1 Oshika, Shizuoka, 422-8527, Japan
| | - Hideki Yasui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| | - Hironao Hozumi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| | - Yuzo Suzuki
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| | - Kazuki Furuhashi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| | - Noriyuki Enomoto
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| | - Tomoyuki Fujisawa
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan
| |
Collapse
|
5
|
Harada M, Yasuda K, Uruchida K, Yamashita R, Morikawa K, Ito Y, Mochizuki E, Matsuura S, Tsukui M, Koshimizu N. An autopsy case of disseminated Cunninghamella bertholletiae infection in an immunocompetent patient: a case report. BMC Pulm Med 2023; 23:88. [PMID: 36932380 PMCID: PMC10022292 DOI: 10.1186/s12890-023-02382-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2022] [Accepted: 03/03/2023] [Indexed: 03/19/2023] Open
Abstract
BACKGROUND Recently, deaths due to mucormycosis in immunocompromised hosts have increased; however, the clinical and pathological features of mucormycosis are not fully understood, especially in view of the associated high mortality and rare incidence in immunocompetent patients. CASE PRESENTATION We have described a rare autopsy case of a 67-year-old Japanese man with chronic obstructive pulmonary disease who contracted mucormycosis. He had not been on any immunosuppressants, and his immune functions were intact. Since 3 days prior to admission to our hospital, he had experienced progressive dyspnea, productive cough, and fever. Chest computed tomography revealed pleural effusion in the left lower hemithorax and consolidation in the right lung field. Although he was administered with tazobactam-piperacillin hydrate (13.5 g/day), renal dysfunction occurred on the ninth disease day. Therefore, it was switched to cefepime (2 g/day). However, his general condition and lung-field abnormality worsened gradually. Cytological analysis of the sputum sample at admission mainly revealed sporangiophores and unicellular sporangioles, while repeated sputum culture yielded Cunninghamella species. Therefore, he was diagnosed with pulmonary mucormycosis. Liposomal amphotericin B (5 mg/kg/day) was initiated on the 28th disease day. However, chest radiography and electrocardiography detected cardiomegaly and atrial fibrillation, respectively, and he died on the 37th disease day. A postmortem examination revealed clusters of fungal hyphae within the arteries of the right pulmonary cavity wall, the subpericardial artery, intramyocardial capillary blood vessels, and the esophageal subserosa vein. Direct sequencing revealed that all fungal culture samples were positive for Cunninghamella bertholletiae. CONCLUSIONS Cunninghamella bertholletiae could rapidly progress from colonizing the bronchi to infecting the surrounding organs via vascular invasion even in immunocompetent patients.
Collapse
Affiliation(s)
- Masanori Harada
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan.
- Department of Respiratory Medicine, Iwata City Hospital, Okubo, Iwata, Shizuoka, 512-3426-8677, Japan.
| | - Kazuyo Yasuda
- Department of Pathology, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Kazumi Uruchida
- Department of Bacterial Laboratory, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Ryoma Yamashita
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Keisuke Morikawa
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Yutaro Ito
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Eisuke Mochizuki
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Masaru Tsukui
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Naoki Koshimizu
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| |
Collapse
|
6
|
Koda K, Enomoto Y, Aoshima Y, Amano Y, Kato S, Hasegawa H, Matsui T, Yokomura K, Mochizuki E, Matsuura S, Koshimizu N, Morita M, Kojima S, Watanabe A, Oyama Y, Ikeda M, Kusagaya H, Uto T, Sato J, Imokawa S, Kono M, Hashimoto D, Kamiya Y, Toyoshima M, Asada K, Morita M, Mikamo M, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suda T. Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. Ther Adv Chronic Dis 2022; 13:20406223221108395. [PMID: 35782342 PMCID: PMC9243372 DOI: 10.1177/20406223221108395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Accepted: 06/01/2022] [Indexed: 11/15/2022] Open
Abstract
Introduction: Although recent advances in chemotherapy for lung cancer are remarkable, most clinical trials have excluded patients with interstitial lung disease (ILD) due to the concern of developing acute exacerbation (AE) of ILD. Hence, accumulating original evidence of cancer treatment for this population is important. Methods: Between 2016 and 2020, a prospective observational study was conducted across 11 Japanese hospitals. Patients with chemotherapy-naïve, inoperable, advanced lung cancer with ILD were included. The primary outcome was the frequency of AE-ILD after registration; the secondary outcomes were the risk factor of AE-ILD and the efficacy of chemotherapy. Results: Among 124 patients enrolled, 109 patients who received chemotherapy were analyzed. The median age was 72 years, and the majority showed usual interstitial pneumonia (UIP)/probable UIP pattern upon chest computed tomography. The median percent-predicted forced vital capacity (%FVC) was 81% (interquartile range: 66–95%). After registration, 23 patients (21.1%; 95% confidence interval [CI]: 14.4–29.7%) developed AE-ILD. The logistic analysis revealed that lower %FVC slightly but significantly increased the risk of AE-ILD (odds ratio per 10% decrease: 1.27; 95% CI: > 1.00–1.62). Overall response rates/median overall survival times in non-small-cell lung cancer and small-cell lung cancer for the first-line chemotherapy were 41% (95% CI: 31–53)/8.9 months (95% CI: 7.6–11.8) and 91% (95% CI: 76–98)/12.2 months (95% CI: 9.2–14.5), respectively. Conclusion: AE-ILD during chemotherapy is a frequent complication among patients with lung cancer with ILD, particularly those with lower %FVC. Conversely, even in this population, passable treatment response can be expected.
Collapse
Affiliation(s)
- Keigo Koda
- Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan
| | | | - Yoichiro Aoshima
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yusuke Amano
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Shinpei Kato
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Hirotsugu Hasegawa
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Takashi Matsui
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Koshi Yokomura
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Eisuke Mochizuki
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Naoki Koshimizu
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Meiko Morita
- Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
| | - Suguru Kojima
- Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
| | - Ayano Watanabe
- Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
| | - Yoshiyuki Oyama
- Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
| | - Masaki Ikeda
- Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
| | - Hideki Kusagaya
- Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
| | - Tomohiro Uto
- Division of Respiratory Medicine, Iwata City Hospital, Iwata, Japan
| | - Jun Sato
- Division of Respiratory Medicine, Iwata City Hospital, Iwata, Japan
| | - Shiro Imokawa
- Division of Respiratory Medicine, Iwata City Hospital, Iwata, Japan
| | - Masato Kono
- Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan
| | - Dai Hashimoto
- Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan
| | - Yosuke Kamiya
- Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan
| | - Mikio Toyoshima
- Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan
| | - Kazuhiro Asada
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - Masako Morita
- Department of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - Masashi Mikamo
- Department of Respiratory Medicine, Hamamatsu Medical Center, Hamamatsu, Japan
| | - Hideki Yasui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hironao Hozumi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Masato Karayama
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yuzo Suzuki
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kazuki Furuhashi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Tomoyuki Fujisawa
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Noriyuki Enomoto
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yutaro Nakamura
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Naoki Inui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
7
|
Matsuura S, Shibazaki K, Uchida R, Imai Y, Mukoyama T, Shibata S, Morita H. Sarcopenia is associated with the Geriatric Nutritional Risk Index in elderly patients with poorly controlled type-2 diabetic mellitus. J Diabetes Investig 2022; 13:1366-1373. [PMID: 35290727 PMCID: PMC9340875 DOI: 10.1111/jdi.13792] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 03/06/2022] [Accepted: 03/13/2022] [Indexed: 11/28/2022] Open
Abstract
Aims/Introduction Diabetes and sarcopenia have a two‐way relationship with each other with advanced age. Additionally, malnutrition is correlated with a higher risk of sarcopenia in elderly patients. This study evaluated the association between sarcopenia and geriatric nutritional risk index (GNRI) in elderly patients with type 2 diabetes mellitus. Materials and Methods Patients with type 2 diabetes mellitus aged ≥60 years were recruited from June 2018 to August 2020. This study analyzed 234 patients, who completed a physical performance test required for the diagnosis of sarcopenia. To investigate the effect of GNRI on sarcopenia, logistic regression analyses was used. Results Patients with sarcopenia were significantly older with a lower body mass index (BMI) and GNRI compared with normal patients. The GNRI showed a positive correlation with the skeletal muscle index (SMI) and handgrip strength (SMI: R = 0.486, P < 0.001 for male; R = 0.589, P < 0.001 for female, handgrip strength: R = 0.470, P < 0.001 for male, R = 0.364, P < 0.001 for female). In the multivariate logistic regression model, a higher GNRI was associated with a lower risk of sarcopenia in older men and women with diabetes (adjusted odds ratio [OR], 0.892; 95% confidence interval [CI], 0.839–0.948 for male; adjusted OR, 0.928; 95% CI, 0.876–0.982 for female). One year of diabetes treatment improved the GNRI in the sarcopenia group with type 2 diabetes mellitus. Conclusions A low GNRI was associated with an increased risk of sarcopenia in elderly patients with type 2 diabetes mellitus. Treatment with glucose‐lowering drugs improved the GNRI in the sarcopenia group.
Collapse
Affiliation(s)
- Shun Matsuura
- Division of Diabetes Endocrinology medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan.,Division of Respiratory Internal medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Koji Shibazaki
- Division of Diabetes Endocrinology medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Reiko Uchida
- Division of Diabetes Endocrinology medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Yukiko Imai
- Division of Diabetes Endocrinology medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Takuya Mukoyama
- Division of Diabetes Endocrinology medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Shoko Shibata
- Division of Diabetes Endocrinology medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Hiroshi Morita
- Division of Diabetes Endocrinology medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| |
Collapse
|
8
|
Mochizuki E, Ito Y, Kagoo N, Kubota T, Mochizuka Y, Naoi H, Matsuura S, Tsukui M, Koshimizu N. Alkaline phosphatase flare phenomenon following treatment of lung adenocarcinoma with Osimertinib: A case report. Current Problems in Cancer: Case Reports 2021. [DOI: 10.1016/j.cpccr.2021.100113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Miyashita K, Karayama M, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kono M, Matsui T, Niwa M, Koda K, Toyoshima M, Matsushima S, Matsuura S, Asada K, Fujii M, Kusagaya H, Matsuda H, Inui N, Suda T. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. BMC Pulm Med 2021; 21:309. [PMID: 34600514 PMCID: PMC8487118 DOI: 10.1186/s12890-021-01681-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Accepted: 09/29/2021] [Indexed: 11/30/2022] Open
Abstract
Background Clinical efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC) with uncommon histology (uNSCLC) is unknown. Methods Patients with NSCLC treated with ICI monotherapy between January 2014 and December 2018 in 10 Japanese hospitals were retrospectively evaluated. The patients were divided into: (1) NSCLC with common histology (cNSCLC), defined as adenocarcinoma and squamous cell carcinoma; and (2) uNSCLC, defined as incompatibility with morphological and immunohistochemical criteria for adenocarcinoma or squamous cell carcinoma. Propensity score matching was performed to balance the two groups. Results Among a total of 175 patients included, 44 with uNSCLC (10 pleomorphic carcinomas, 9 large cell neuroendocrine carcinomas, 2 large cell carcinomas, and 23 not otherwise specified) and 44 with matched cNSCLC (32 adenocarcinomas and 12 squamous cell carcinomas) were selected for analyses. Median progression-free survival (PFS) (4.4 months, 95% confidence interval [CI] 1.8–7.7 months) and overall survival (OS) (11.4 months, 95% CI 7.4–27.4 months) in the uNSCLC patients were not significantly different from those in matched cNSCLC patients (5.4 months, 95% CI 3.1–7.6 months, p = 0.761; and 14.1 months, 95% CI 10.6–29.6 months, p = 0.381). In multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0–1 and programmed death ligand-1 (PD-L1) expression were predictive for PFS and OS in uNSCLC. Conclusions ICIs had similar clinical efficacy for treatment of uNSCLC and cNSCLC. Good ECOG-PS and PD-L1 expression were predictive for efficacy of ICIs in uNSCLC. Supplementary Information The online version contains supplementary material available at 10.1186/s12890-021-01681-6.
Collapse
Affiliation(s)
- Koichi Miyashita
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Masato Karayama
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.
| | - Yusuke Inoue
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Hironao Hozumi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Yuzo Suzuki
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Kazuki Furuhashi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Tomoyuki Fujisawa
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Noriyuki Enomoto
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Yutaro Nakamura
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.,Department of Chemotherapy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Masato Kono
- Department of Respiratory Medicine, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Hamamatsu, 430-8558, Japan
| | - Takashi Matsui
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, 3453 Mikatahara-cho, Hamamatsu, 433-8558, Japan
| | - Mitsuru Niwa
- Department of Respiratory Medicine, Hamamatsu Medical Center, 328 Tomitsuka-cho, Hamamatsu, 432-8580, Japan
| | - Keigo Koda
- Department of Respiratory Medicine, Hamamatsu Rosai Hospital, 25 Shougen-cho, Hamamatsu, 430-8525, Japan
| | - Mikio Toyoshima
- Department of Respiratory Medicine, Hamamatsu Rosai Hospital, 25 Shougen-cho, Hamamatsu, 430-8525, Japan
| | - Sayomi Matsushima
- Department of Respiratory Medicine, Iwata City Hospital, 513-2 Ohkubo, Iwata, 438-8550, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, 426-8677, Japan
| | - Kazuhiro Asada
- Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-ando, Shizuoka, 420-0881, Japan
| | - Masato Fujii
- Department of Respiratory Medicine, Shizuoka City Hospital, 10-93 Ote-cho, Shizuoka, 420-8630, Japan
| | - Hideki Kusagaya
- Department of Respiratory Medicine, Shizuoka Saiseikai Hospital, 1-1-1 Oshika, Shizuoka, 422- 8527, Japan
| | - Hiroyuki Matsuda
- Department of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital, 8-2 Otemachi, Shizuoka, 420-0853, Japan
| | - Naoki Inui
- Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| |
Collapse
|
10
|
Matsuura S, Morikawa K, Ito Y, Kubota T, Ichijo K, Mochizuki E, Akiyama N, Uehara M, Harada M, Tsukui M, Koshimizu N. The Geriatric Nutritional Risk Index and Prognostic Nutritional Index Predict the Overall Survival of Advanced Non-Small Cell Lung Cancer Patients. Nutr Cancer 2021; 74:1606-1613. [PMID: 34431441 DOI: 10.1080/01635581.2021.1960387] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
We aimed to assess the prognostic and predictive significance of pretreatment Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) measurements on advanced non-small cell lung cancer (NSCLC) patients treated with first-line therapy. Patients with advanced NSCLC treated between February 2014 and August 2020 were retrospectively analyzed. The optimal cutoff points for GNRI and PNI were measured with receiver operating characteristic (ROC) curve analysis according to overall survival (OS). The predictive factors for progression-free survival (PFS) and OS were evaluated with univariate and multivariate analyses via the Cox hazards regression. A total of 160 patients were included in the study. Significant differences between the low and high-GNRI or PNI groups were found regarding ECOG-PS. The low-GNRI and low-PNI groups had significantly shorter PFS and OS than the high-GNRI and high-PNI groups. A multivariate analysis using a Cox regression model revealed that the high-GNRI group was an independent prognostic factor of OS and PFS, and the PNI group was an independent prognostic factor of OS. Pretreatment GNRI and PNI may therefore be a potential effective predictor of the survival of advanced NSCLC patients undergoing first-line treatment.
Collapse
Affiliation(s)
- Shun Matsuura
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Keisuke Morikawa
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Yutaro Ito
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Tsutomu Kubota
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Koshiro Ichijo
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Eisuke Mochizuki
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Norimichi Akiyama
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Masahiro Uehara
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Masanori Harada
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Masaru Tsukui
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| | - Naoki Koshimizu
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Fujieda, Shizuoka, Japan
| |
Collapse
|
11
|
Matsuura S. Bayes estimator of process capability index Cpk with a specified prior mean. COMMUN STAT-THEOR M 2021. [DOI: 10.1080/03610926.2021.1947508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Shun Matsuura
- Faculty of Science and Technology, Keio University, Tokyo, Japan
| |
Collapse
|
12
|
Harada M, Morikawa K, Kagoo N, Ito Y, Kubota T, Ichijo K, Mochizuki E, Uehara M, Matsuura S, Yasuda K, Tsukui M, Koshimizu N. Argon plasma coagulation with atezolizumab and chemoradiation in lung pleomorphic cancer showed a remarkable response: Case report. Medicine (Baltimore) 2021; 100:e26149. [PMID: 34032770 PMCID: PMC8154453 DOI: 10.1097/md.0000000000026149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Accepted: 05/11/2021] [Indexed: 01/04/2023] Open
Abstract
RATIONALE Lung pleomorphic carcinoma (LPC) is generally resistant to chemotherapy or radiotherapy. However, a combination of immune checkpoint inhibitors and radiotherapy has a remarkable efficacy against LPC. PATIENT CONCERNS AND DIAGNOSES Here, we report the case of a 50-year old man diagnosed with progressive LPC. The tumor invaded the carina and predominantly obstructed the right main bronchus; therefore, a combination of palliative chemoradiotherapy and atezolizumab was initiated. However the trachea was gradually obstructed. INTERVENTION AND OUTCOME Argon plasma coagulation (APC) was performed to prevent tumor invasion. After three APC sessions, the tumor showed a necrotic change and was easily excised using biopsy forceps. LESSONS A combination of chemoradiotherapy, atezolizumab, and APC showed a good efficacy, and the patient had a good response to atezolizumab maintenance therapy. Multidisciplinary treatments, such as a combination of immune checkpoint inhibitors and APC, could have synergistic efficacy in lung cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Kazuyo Yasuda
- Department of pathology, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, Japan
| | | | | |
Collapse
|
13
|
Harada M, Naoi H, Yasuda K, Ito Y, Kagoo N, Kubota T, Ichijo K, Mochizuki E, Uehara M, Matsuura S, Tsukui M, Koshimizu N. Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report. BMC Pulm Med 2021; 21:6. [PMID: 33407304 PMCID: PMC7789237 DOI: 10.1186/s12890-020-01375-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Accepted: 12/14/2020] [Indexed: 02/04/2023] Open
Abstract
Background Immune checkpoint inhibitors have potential applications in treating various cancers but are associated with immune-related adverse events, such as inflammation, in a wide range of organs; however, allergic inflammation caused by these agents has not been extensively studied. Case presentation A 65-year-old man was diagnosed with a kidney neuroendocrine carcinoma. Three months after kidney resection surgery, the tumor cells had metastasized to his liver and lymph nodes. Subsequently, the patient started chemotherapy; however, regardless of treatment, the tumor grew, and the patient experienced a series of adverse effects, such as taste disorder, anorexia, and general fatigue. Finally, he was administered a programmed cell death (PD)-1 inhibitor, nivolumab (biweekly, toal 200 mg/body), which was effective against kidney carcinoma. However, the patient had a bronchial asthma attack at 22 cycles of nivolumab treatment and chest computed tomography (CT) revealed an abnormal bilateral shadow after 37 cycles of nivolumab treatment. Bronchoscopy findings revealed eosinophil infiltration in the lungs along with severe alveolar hemorrhage. Paranasal sinus CT scanning indicated sinusitis and nerve conduction analysis indicated a decrease in his right ulnar nerve conduction velocity. Based on these findings, the patient was diagnosed with eosinophilic granulomatosis with polyangiitis; he was treated with prednisolone, which alleviated his bronchial asthma. To restart nivolumab treatment, the dose of prednisolone was gradually tapered, and the patient was administered a monthly dose of mepolizumab and biweekly dose of nivolumab. To date, there have been no bronchial attacks or CT scan abnormalities upon follow up. Conclusions We present a rare case in which a patient with cancer was diagnosed with eosinophilic granulomatosis with polyangiitis following treatment with a PD-1 inhibitor. Blockade of PD-1 and the programmed cell death ligand (PD-L) 1/PD-1 and PD-L2/PD-1 signaling cascade may cause allergic inflammation. Further studies are needed to identify the specific mechanisms underlying allergic inflammation after PD-1 blockade.
Collapse
Affiliation(s)
- Masanori Harada
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan.
| | - Hyogo Naoi
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Kazuyo Yasuda
- Department of Pathology, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Yutaro Ito
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Namio Kagoo
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Tsutomu Kubota
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Koshiro Ichijo
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Eisuke Mochizuki
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Masahiro Uehara
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Masaru Tsukui
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| | - Naoki Koshimizu
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda City, Shizuoka Province, Japan
| |
Collapse
|
14
|
Affiliation(s)
- Kohei Fujiwara
- Graduate School of Science and Technology, Keio University, Yokohama, Kanagawa, Japan
| | - Shun Matsuura
- Faculty of Science and Technology, Keio University, Yokohama, Kanagawa, Japan
| |
Collapse
|
15
|
Mochizuki E, Kawai Y, Morikawa K, Ito Y, Kagoo N, Kubota T, Ichijyo K, Uehara M, Harada M, Matsuura S, Tsukui M, Koshimizu N. Difference in Local Lung Movement During Tidal Breathing Between COPD Patients and Asthma Patients Assessed by Four-dimensional Dynamic-ventilation CT Scan. Int J Chron Obstruct Pulmon Dis 2020; 15:3013-3023. [PMID: 33244227 PMCID: PMC7685382 DOI: 10.2147/copd.s273425] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 10/27/2020] [Indexed: 11/23/2022] Open
Abstract
Background The validity of four-dimensional dynamic-ventilation CT scan for distinguishing COPD from asthma has not been established. Purpose To assess whether four-dimensional dynamic-ventilation CT scan can aid in the diagnosis of COPD by comparing local lung movement during tidal breathing between COPD and asthma. Patients and Methods Thirty-three COPD patients (30 males and three females; median age 74; range 44-89 years) and 11 asthma patients (five males and six females; median age 55; range: 32-75 years) underwent whole-lung dynamic-ventilation CT scan. CT data were reconstructed, one respiratory cycle to 10 phases, and in addtion we reconstructed threefold new phase data sets. We then analyzed local lung movement during tidal breathing using unpaired t-tests and chi-squared tests. Results The local lung movement in COPD patients was significantly smaller than in asthma patients, especially in the ventral part of the lung. This was so even in patients who had mild emphysema (Goddard score <8). Conclusion Quantitative evaluation using four-dimensional dynamic-ventilation CT scan demonstrated that local lung movement during tidal breathing, particularly in the ventral lung, was smaller in COPD than in asthma patients, which may help distinguish COPD from asthma.
Collapse
Affiliation(s)
- Eisuke Mochizuki
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Yoshiihiro Kawai
- Department of Radiology, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Keisuke Morikawa
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Yutaro Ito
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Namio Kagoo
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Tsutomu Kubota
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Koshiro Ichijyo
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Masahiro Uehara
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Masanori Harada
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Masaru Tsukui
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| | - Naoki Koshimizu
- Department of Respiratory Medicine, Fujieda Municipal Hospital, Fujieda 426-8677, Japan
| |
Collapse
|
16
|
Takashima S, Usui S, Matsuura S, Goten C, Inoue O, Ohtani K, Kubota K, Sakata K, Kawashiri M, Takamura M. Bone marrow-derived NGFR+ cells regulate arterial remodeling and those poor mobilizations in peripheral blood in acute coronary syndrome predicts plaque progression at the non-targeted lesion. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
In our previous 5-year cohort study, we demonstrated that low gene expression of nerve growth factor receptor (NGFR) in peripheral leucocytes in acute coronary syndrome (ACS) predicted repetitive coronary interventions at the de novo lesions. An NGFR-positive cell has been demonstrated to reside in bone marrow (BM) stromal fraction and to be increased in peripheral blood mononuclear cell (MNCs) fraction in patients with ischemic heart disease.
Purpose
To investigate whether the BM-NGFR+ cell is associated with arterial remodeling and the relationship between the levels of peripheral NGFR+ cells after ACS and coronary plaque progression in an experimental and prospective clinical study.
Methods and results
In an experimental study, 8-week-old C57B6/J wild type male mice were subjected to irradiation with 9.6 Gy and transplantation with BM (BMT) isolated from GFP-transgenic NGFR wild type (WT) or knock-out (KO) mice at day 1. Four weeks after BMT, the right carotid artery was ligated for 4 weeks. Induced neointimal area was increased (p<0.05), where cells under apoptosis were decreased (p<0.05) in NGFR-KO-BMT group compared to WT-BMT group (n=4). NGFR+ cells were not detected in wild type sham-operated artery, whereas in the ligated artery in WT-BMT group NGFR+ cells assembled in the developed neointima and exclusively presented double positive with GFP, but absent in NGFR-KO-BMT group (p<0.05, n=4). In a clinical study, thirty patients with ACS who underwent primary percutaneous coronary intervention (PCI) were enrolled. The peripheral blood sample was collected on days 0, 3 and 7, and 9 months follow-up and the number of NGFR+MNCs were measured by flowcytometric analysis. The plaque volume at non-targeted coronary lesion (non-TL:>5 mm proximal or distal to the implanted stents) were quantitatively analysed using gray-scale intravascular ultrasound (IVUS) and Q-IVUS™ software at the acute phase and 9 months follow-up. The number of NGFR+MNCs in peripheral blood was 1.5-fold increased at day 3 (0.064±0.056%) compared to day 0 (0.042±0.030%) (p<0.05). The change in normalized total plaque volume (TAVN) at non-TL at 9 months was negatively correlated with the number of NGFR+MNCs at day 0 (r=−0.51), day 3 (r=−0.51) and 9 months (r=−0.59) after ACS (p<0.05). Multiple regression analysis showed that NGFR+MNCs at day 0 (β=−0.48, p=0.01) and CRP (β=−0.53, P<0.01) are independent factors associating with TAVN change at non-TL at 9 months, regardless of LDL-cholesterol control level. ROC analysis revealed that NGFR+MNCs <0.049 at day 0 predicted the increase of TAVN with AUC 0.78; sensitivity 0.82 and specificity 0.67.
Conclusions
Bone marrow-derived peripheral NGFR+ cells negatively regulate arterial remodeling through appropriate apoptosis of neointimal cells and the peripheral level of NGFR+ cells in ACS predicts plaque progression at the non-targeted lesion.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): KAKENHI
Collapse
Affiliation(s)
- S Takashima
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| | - S Usui
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| | - S Matsuura
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| | - C Goten
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| | - O Inoue
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| | - K Ohtani
- Public Central Hospital of Matto Ishikawa, Hakusan, Japan
| | - K Kubota
- Public Central Hospital of Matto Ishikawa, Hakusan, Japan
| | - K Sakata
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| | - M Kawashiri
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| | - M Takamura
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| |
Collapse
|
17
|
Matsuura S, Morikawa K, Ito Y, Kagoo N, Kubota T, Ichijo K, Mochizuki E, Uehara M, Harada M, Tsukui M, Koshimizu N. Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report. Respir Med Case Rep 2020; 31:101236. [PMID: 33083220 PMCID: PMC7552097 DOI: 10.1016/j.rmcr.2020.101236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 09/23/2020] [Accepted: 09/24/2020] [Indexed: 11/15/2022] Open
Abstract
Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 insertion adenocarcinoma with high-expression programmed cell death ligand 1 (PD-L1). He showed stable disease to chemoradiation treatment at the primary tumor site. However, durvalumab treatment has good response. Non-small cell lung cancer with EGFR exon 20 insertion and high PD-L1 expression may be treated with immunotherapy exposure.
Collapse
Affiliation(s)
- Shun Matsuura
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Keisuke Morikawa
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Yutaro Ito
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Namio Kagoo
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Tsutomu Kubota
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Koshiro Ichijo
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Eisuke Mochizuki
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Masahiro Uehara
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Masanori Harada
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Masaru Tsukui
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| | - Naoki Koshimizu
- Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, Japan
| |
Collapse
|
18
|
Ito Y, Harada M, Kagoo N, Kubota T, Ichijyo K, Mochizuki E, Uehara M, Matsuura S, Tsukui M, Koshimizu N. Axillary lymphadenopathy with IgG4 positive plasma cell infiltration as differential diagnosis of metastatic lung adenocarcinoma. Respir Med Case Rep 2020; 31:101196. [PMID: 32913702 PMCID: PMC7472920 DOI: 10.1016/j.rmcr.2020.101196] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 08/12/2020] [Accepted: 08/13/2020] [Indexed: 12/24/2022] Open
Abstract
Immunoglobulin type G4 -related disease (IgG4-RD) is known as a chronic systemic inflammatory disease, which is sometimes associated with lung cancer. However, the detailed association between IgG4-RD and lung cancer in clinical settings is still poorly understood. An 80-year-old man was diagnosed with progressive lung adenocarcinoma carrying an EGFR point mutation at L858R, and osimertinib treatment was administered. Two months later, although osimertinib treatment showed good response to the primary tumor, fever and anorexia appeared, and multiple lymph nodes, in particular in the left axillary, became swollen. Ultrasonography-guided biopsy of the axillary lymph node revealed infiltration of lymphocytes with IgG4-positive plasma cells and fibrosis. Serum IgG4 levels were also increased. These results suggested that the multiple swollen lymph nodes were not metastasis, but IgG4-related disease. Based on these results, therapy using prednisolone was initiated. Multiple lymphadenopathy gradually decreased, and his symptoms improved. Currently, his good responses to osimertinib treatment have been maintained. Like in our case, multiple lymphadenopathy with IgG4-positive plasma cell infiltration during successful anti-cancer treatment is quite rare. In this case, it was hypothesized that anti-cancer treatment with osimertinib induced IgG4-positive plasma cell infiltration in multiple lymph nodes. When lymphadenopathy occurs during lung cancer treatment, IgG4-RD has to be considered other than lung cancer metastasis.
Collapse
Affiliation(s)
| | - Masanori Harada
- Corresponding author. Department of Respirology, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, 426-8677, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Inoue Y, Yoshimura K, Nishimoto K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Kusagaya H, Matsuda H, Inami N, Kaida Y, Niwa M, Ito Y, Sugimura H, Suda T. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. JAMA Netw Open 2020; 3:e2011818. [PMID: 32955570 PMCID: PMC7506518 DOI: 10.1001/jamanetworkopen.2020.11818] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
IMPORTANCE Robust predictors for response to anti-programmed death 1 and its ligand (PD-1/PD-L1) immunotherapy in non-small cell lung cancer (NSCLC) are not fully characterized. OBJECTIVE To evaluate whether PD-L1 (CD274) copy number gains (CNGs), comprising amplification and polysomy, in pretreatment specimens assessed by fluorescence in situ hybridization are associated with response to nivolumab monotherapy in NSCLC. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study enrolled 200 patients, of whom 194 had assessable tumors, with advanced or recurrent NSCLC who were treated with nivolumab after progression following prior treatment at 14 institutions in Japan between July 2016 and December 2018. Median (interquartile range) duration of follow-up was 12.6 (5.6-20.4) months. Data were analyzed from December 2019 to February 2020. EXPOSURES Sequential nivolumab was given on day 1 of a 14-day cycle. Response was assessed every 4 cycles using Response Evaluation Criteria in Solid Tumors version 1.1. MAIN OUTCOMES AND MEASURES Overall response rate (ORR) according to the PD-L1 copy number status. Additional end points were progression-free survival, overall survival, and PD-L1 tumor proportion score (TPS) assessed by immunohistochemistry based on PD-L1 copy number status. RESULTS A total of 6 of the 200 patients were excluded because of poor-quality tumor specimens for the biomarker study, resulting in 194 assessable patients. Of these, 155 (79.9%) were men, with a median (range) age of 69 (43-83) years. PD-L1 CNGs were identified in 32 patients (16.5%), including 5 (2.6%) with amplification and 27 (13.9%) with polysomy. The ORR among patients with and without PD-L1 CNGs was 28.1% (95% CI, 13.7%-46.7%) and 17.9% (95% CI, 12.3%-24.7%), respectively. Although patients with PD-L1 polysomy did not demonstrate improved ORR (18.5% [95% CI, 6.3%-38.1%]) compared with those without PD-L1 CNGs, 4 of 5 patients (80.0% [95% CI, 28.4%-99.5%]) with PD-L1 amplification showed response, among whom median duration of response was not reached. Patients with PD-L1 amplification showed excellent survival outcomes for progression-free and overall survival. Overall, 3 PD-L1-amplified tumors (60.0%) showed PD-L1 TPS of at least 80%, but 2 (40.0%) had PD-L1 TPS of 15% or less. CONCLUSIONS AND RELEVANCE In this study, tumor PD-L1 amplification but not polysomy was associated with response to nivolumab monotherapy among patients with NSCLC. External validation with a larger sample size is warranted.
Collapse
Affiliation(s)
- Yusuke Inoue
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Katsuhiro Yoshimura
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Koji Nishimoto
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Naoki Inui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Masato Karayama
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Department of Clinical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hideki Yasui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hironao Hozumi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yuzo Suzuki
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kazuki Furuhashi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Tomoyuki Fujisawa
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Noriyuki Enomoto
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yutaro Nakamura
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kazuhiro Asada
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
| | - Tomohiro Uto
- Department of Respiratory Medicine, Iwata City Hospital, Iwata, Japan
| | - Masato Fujii
- Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
| | - Takashi Matsui
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Dai Hashimoto
- Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan
| | - Mikio Toyoshima
- Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan
| | - Hideki Kusagaya
- Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
| | - Hiroyuki Matsuda
- Department of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - Nao Inami
- Department of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan
| | - Yusuke Kaida
- Department of Respiratory Medicine, Ensyu Hospital, Hamamatsu, Japan
| | - Mitsuru Niwa
- Department of Respiratory Medicine, Hamamatsu Medical Center, Hamamatsu, Japan
| | - Yasuhiro Ito
- Department of Respiratory Medicine, Tenryu Hospital, National Hospital Organization, Hamamatsu, Japan
| | - Haruhiko Sugimura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
20
|
Matsuura S, Kurata H. Covariance matrix estimation in a seemingly unrelated regression model under Stein’s loss. STAT METHOD APPL-GER 2020. [DOI: 10.1007/s10260-019-00473-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
21
|
Collins S, Kamath P, Matsuura S, Jolly D, Slomovitz B, Kasahara N. Therapeutic efficacy of vocimagene amiretrorepvec (Toca 511) prodrug activator gene therapy in peritoneal carcinomatosis models of ovarian cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.03.231] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Mochizuki E, Matsuura S, Kubota T, Mochizuka Y, Oishi K, Naoi H, Uehara M, Mikura S, Nagaoka M, Tsukui M, Koshimizu N, Nameki I. Sinobronchial allergic mycosis syndrome in an elderly male. Allergy Asthma Clin Immunol 2019; 15:35. [PMID: 31171926 PMCID: PMC6549302 DOI: 10.1186/s13223-019-0349-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Accepted: 05/30/2019] [Indexed: 12/29/2022] Open
Abstract
Background Allergic bronchopulmonary aspergillosis (ABPA) and allergic fungal rhinosinusitis (AFRS) are characterized by hyper-responsiveness of the respiratory tract and the nasal cavity and paranasal sinuses, respectively to Aspergillus species and AFRS causes chronic rhinosinusitis. Herein, we report the first case of sinobronchial allergic mycosis (SAM) syndrome, defined as ABPA with concomitant AFRS, caused by Aspergillus fumigatus patient > 80 years. Case presentation An 82-year-old male with interstitial pneumonia who returned for follow-up exhibited high-attenuation mucus plug in the right intermediate bronchial trunk, infiltration in the right lung field, and right pleural effusion on regular chest computed tomography (CT). We found unilateral central bronchiectasis in the right upper lobe. Similarly, CT scan of the paranasal sinuses revealed high-attenuation mucus plugs in left ethmoid sinuses. Biopsy specimens from the plugs in the right intermediate bronchial trunk and the left ethmoid sinuses revealed allergic mucin with layers of mucus eosinophils, eosinophil-predominant mixed inflammatory cell infiltrate and Aspergillus hyphae. The patient fulfilled all the major criteria for ABPA and AFRS, and was diagnosed with SAM syndrome. CT scan of the lung and paranasal sinuses revealed apparent amelioration after oral steroid therapy. Conclusion Despite mostly reported in relatively young patients, SAM syndrome can occur in elderly individuals as well.
Collapse
Affiliation(s)
- Eisuke Mochizuki
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Tsutomu Kubota
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Yasutaka Mochizuka
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Kyohei Oishi
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Hyogo Naoi
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Masahiro Uehara
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Shinichiro Mikura
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Miyuki Nagaoka
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Masaru Tsukui
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Naoki Koshimizu
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| | - Ichirota Nameki
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan.,Department of Otological Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, 426-8677 Japan
| |
Collapse
|
23
|
Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kusagaya H, Matsuura S, Uto T, Hashimoto D, Matsui T, Asada K, Suda T. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 2019; 84:147-153. [PMID: 31087137 DOI: 10.1007/s00280-019-03868-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 05/04/2019] [Indexed: 10/26/2022]
Abstract
PURPOSE There remains an unmet clinical need for the control of chemotherapy-induced nausea and vomiting (CINV), particularly in the prevention of nausea and the delayed phase control. We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and dexamethasone in patients receiving carboplatin-containing chemotherapy. Olanzapine inhibits signalling via multiple neurotransmitter receptors involved in CINV. METHODS Chemotherapy-naïve patients with lung cancer who received carboplatin-containing chemotherapy were enrolled in this phase-II study. Patients received olanzapine, aprepitant, a 5-HT3 receptor antagonist and dexamethasone. The primary endpoint was the complete response rate (no vomiting and no rescue therapy) during 120 h after administration of chemotherapy agents. RESULTS Thirty-three patients received olanzapine-containing antiemetic therapy. The overall complete response rate was 93.3% (95% confidence interval, 80.4-98.3%). The frequency of nausea was 15.2% in the delayed phase and 18.2% in the overall phase. Somnolence was observed in 16 patients. CONCLUSION Adding olanzapine to antiemetic therapy with aprepitant, a 5-HT3 receptor antagonist and dexamethasone improved CINV control in patients receiving carboplatin-containing chemotherapy.
Collapse
Affiliation(s)
- Kazuki Tanaka
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Naoki Inui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan. .,Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.
| | - Masato Karayama
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.,Department of Clinical Oncology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Hideki Yasui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Hironao Hozumi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Yuzo Suzuki
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Kazuki Furuhashi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Tomoyuki Fujisawa
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Noriyuki Enomoto
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Yutaro Nakamura
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| | - Hideki Kusagaya
- Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, 1-1-1 Oshika, Shizuoka, 422-8527, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda, 426-8677, Japan
| | - Tomohiro Uto
- Department of Respiratory Medicine, Iwata City Hospital, 513-2 Ohkubo, Iwata, 438-8550, Japan
| | - Dai Hashimoto
- Department of Respiratory Medicine, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi-cho, Hamamatsu, 430-8558, Japan
| | - Takashi Matsui
- Department of Respiratory Medicine, Seirei Mikatahara General Hospital, 3453 Mikatahara-cho, Hamamatsu, 433-8558, Japan
| | - Kazuhiro Asada
- Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-ando, Shizuoka, 420-0881, Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan
| |
Collapse
|
24
|
Kitazato K, Milliken RE, Iwata T, Abe M, Ohtake M, Matsuura S, Arai T, Nakauchi Y, Nakamura T, Matsuoka M, Senshu H, Hirata N, Hiroi T, Pilorget C, Brunetto R, Poulet F, Riu L, Bibring JP, Takir D, Domingue DL, Vilas F, Barucci MA, Perna D, Palomba E, Galiano A, Tsumura K, Osawa T, Komatsu M, Nakato A, Arai T, Takato N, Matsunaga T, Takagi Y, Matsumoto K, Kouyama T, Yokota Y, Tatsumi E, Sakatani N, Yamamoto Y, Okada T, Sugita S, Honda R, Morota T, Kameda S, Sawada H, Honda C, Yamada M, Suzuki H, Yoshioka K, Hayakawa M, Ogawa K, Cho Y, Shirai K, Shimaki Y, Hirata N, Yamaguchi A, Ogawa N, Terui F, Yamaguchi T, Takei Y, Saiki T, Nakazawa S, Tanaka S, Yoshikawa M, Watanabe S, Tsuda Y. The surface composition of asteroid 162173 Ryugu from Hayabusa2 near-infrared spectroscopy. Science 2019; 364:272-275. [PMID: 30890589 DOI: 10.1126/science.aav7432] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Accepted: 03/07/2019] [Indexed: 11/02/2022]
Abstract
The near-Earth asteroid 162173 Ryugu, the target of the Hayabusa2 sample-return mission, is thought to be a primitive carbonaceous object. We report reflectance spectra of Ryugu's surface acquired with the Near-Infrared Spectrometer (NIRS3) on Hayabusa2, to provide direct measurements of the surface composition and geological context for the returned samples. A weak, narrow absorption feature centered at 2.72 micrometers was detected across the entire observed surface, indicating that hydroxyl (OH)-bearing minerals are ubiquitous there. The intensity of the OH feature and low albedo are similar to thermally and/or shock-metamorphosed carbonaceous chondrite meteorites. There are few variations in the OH-band position, which is consistent with Ryugu being a compositionally homogeneous rubble-pile object generated from impact fragments of an undifferentiated aqueously altered parent body.
Collapse
Affiliation(s)
- K Kitazato
- The University of Aizu, Fukushima, Japan.
| | | | - T Iwata
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - M Abe
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - M Ohtake
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | | | - T Arai
- Ashikaga University, Tochigi, Japan
| | - Y Nakauchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | | | - M Matsuoka
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - H Senshu
- Chiba Institute of Technology, Chiba, Japan
| | - N Hirata
- The University of Aizu, Fukushima, Japan
| | - T Hiroi
- Brown University, Providence, RI, USA
| | - C Pilorget
- Institut d'Astrophysique Spatial, Université Paris-Sud, Orsay, France
| | - R Brunetto
- Institut d'Astrophysique Spatial, Université Paris-Sud, Orsay, France
| | - F Poulet
- Institut d'Astrophysique Spatial, Université Paris-Sud, Orsay, France
| | - L Riu
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - J-P Bibring
- Institut d'Astrophysique Spatial, Université Paris-Sud, Orsay, France
| | - D Takir
- Astromaterials Research and Exploration Science, NASA Johnson Space Center, Houston, TX, USA
| | | | - F Vilas
- Planetary Science Institute, Tucson, AZ, USA
| | - M A Barucci
- Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique (LESIA), Observatoire de Paris, Meudon, France
| | - D Perna
- Osservatorio Astronomico di Roma, Istituto Nazionale di Astrofisica (INAF), Monte Porzio Catone, Italy.,Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique (LESIA), Observatoire de Paris, Meudon, France
| | - E Palomba
- Istituto di Astrofisica e Planetologia Spaziali, INAF, Roma, Italy
| | - A Galiano
- Istituto di Astrofisica e Planetologia Spaziali, INAF, Roma, Italy
| | - K Tsumura
- Tohoku University, Sendai, Japan.,Tokyo City University, Tokyo, Japan
| | - T Osawa
- Japan Atomic Energy Agency, Ibaraki, Japan
| | - M Komatsu
- The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - A Nakato
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - T Arai
- Chiba Institute of Technology, Chiba, Japan
| | - N Takato
- National Astronomical Observatory of Japan, Tokyo, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - T Matsunaga
- National Institute for Environmental Studies, Ibaraki, Japan
| | - Y Takagi
- Aichi Toho University, Nagoya, Japan
| | - K Matsumoto
- National Astronomical Observatory of Japan, Tokyo, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - T Kouyama
- National Institute of Advanced Industrial Science and Technology, Tokyo, Japan
| | - Y Yokota
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,Kochi University, Kochi, Japan
| | - E Tatsumi
- The University of Tokyo, Tokyo, Japan
| | - N Sakatani
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - Y Yamamoto
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - T Okada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,The University of Tokyo, Tokyo, Japan
| | - S Sugita
- The University of Tokyo, Tokyo, Japan
| | - R Honda
- Kochi University, Kochi, Japan
| | - T Morota
- Nagoya University, Nagoya, Japan
| | | | - H Sawada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - C Honda
- The University of Aizu, Fukushima, Japan
| | - M Yamada
- Chiba Institute of Technology, Chiba, Japan
| | | | | | - M Hayakawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - K Ogawa
- Kobe University, Kobe, Japan
| | - Y Cho
- The University of Tokyo, Tokyo, Japan
| | - K Shirai
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - Y Shimaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | | | - A Yamaguchi
- National Institute of Polar Research, Tokyo, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - N Ogawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - F Terui
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - T Yamaguchi
- Mitsubishi Electric Corporation, Kanagawa, Japan
| | - Y Takei
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - T Saiki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - S Nakazawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - S Tanaka
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - M Yoshikawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| | - S Watanabe
- Nagoya University, Nagoya, Japan.,Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan
| | - Y Tsuda
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara, Japan.,The Graduate University for Advanced Studies (SOKENDAI), Kanagawa, Japan
| |
Collapse
|
25
|
Uchida H, Yuan Q, Inoue Y, Shinohara K, Matsuura S, Fujiwara Y. MENTAL HEALTH WELL-BEING AND ITS RELATED FACTORS OF THE PARTICIPANTS IN SENIOR CITIZEN’S COLLEGE IN JAPAN. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | | | | | | | - Y Fujiwara
- Tokyo Metropolitan Institute of Gerontology
| |
Collapse
|
26
|
Miyashita K, Matsuura S, Tajima K, Tajima S, Aoki A, Sakagami T, Koshimizu N, Toyoshima M, Suda T. Disseminated Mycobacterium avium Infection Presenting with Bladder Lesions in a Patient with Interferon-γ-neutralizing Autoantibodies. Intern Med 2018; 57:3041-3045. [PMID: 29780147 PMCID: PMC6232015 DOI: 10.2169/internalmedicine.0965-18] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
A 63-year-old woman presented with a fever, eruption, and sterile pyuria. A cystoscopic examination revealed submucosal nodular lesions in the trigone of the bladder, and a biopsy specimen showed epithelioid cell granulomas in the lamina propria of the bladder. Mycobacterium avium grew in the urine culture. Other organ involvement, such as the lungs, spleen, bones, muscles, and pelvic lymph nodes, was observed on radiological examinations, and M. avium was isolated from some organ lesions. Interferon-γ-neutralizing autoantibodies were detected in the patient's serum. Therefore, the patient was diagnosed with disseminated M. avium infection, which was resolved with antimycobacterial treatment.
Collapse
Affiliation(s)
- Koichi Miyashita
- Department of Respiratory Medicine, Fujieda City General Hospital, Japan
- Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda City General Hospital, Japan
| | - Kenichi Tajima
- Department of Urology, Fujieda City General Hospital, Japan
| | - Shogo Tajima
- Department of Pathology, Graduate School of Medicine University of Tokyo, Japan
| | - Ami Aoki
- Department of Respiratory Medicine and Infectious Disease, Niigata University Graduate School of Medical and Dental Sciences, Japan
| | - Takuro Sakagami
- Department of Respiratory Medicine and Infectious Disease, Niigata University Graduate School of Medical and Dental Sciences, Japan
| | - Naoki Koshimizu
- Department of Respiratory Medicine, Fujieda City General Hospital, Japan
| | - Mikio Toyoshima
- Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Japan
| | - Takafumi Suda
- Second Department of Internal Medicine, Hamamatsu University School of Medicine, Japan
| |
Collapse
|
27
|
Mochizuki E, Mochizuka Y, Oishi K, Naoi H, Matsuura S, Mikura S, Nagaoka M, Tsukui M, Koshimizu N. P3.01-73 Talc Versus Minocycline and OK-432 Pleurodesis for Malignant Pleural Effusion. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Takanashi Y, Matsuura S, Neyatani H, Funai K. Tracheal segmental resection for tracheal cancer: comparison of cervical collar incision with median sternotomy and posterolateral incision. J Surg Case Rep 2018; 2018:rjy201. [PMID: 30093998 PMCID: PMC6080050 DOI: 10.1093/jscr/rjy201] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 07/14/2018] [Indexed: 11/14/2022] Open
Abstract
We compare two surgical approaches for segmental tracheal resection for tracheal cancer: cervical collar incision with median sternotomy and right posterolateral incision. In case one, a 46-year-old woman presented with adenoid cystic carcinoma, measuring 4.5 cm longitudinally, located at the junction of the cervical and mediastinal trachea. Cervical collar incision with median sternotomy provided a good exposure of the entire trachea. Although a relatively long tracheal resection (5.0 cm) was required, sufficient mobilization of the entire trachea facilitated low-tension anastomosis. In case 2, a 39-year-old man presented with squamous cell carcinoma, measuring 1.8 cm longitudinally, located at the lower trachea 1.8 cm from the carina to the proximal side. Right posterolateral incision provided a good exposure of the lower trachea. Although the required tracheal resection was relatively short (3.0 cm), the anastomotic tension was high. The high anastomotic tension was likely attributed to the limited mobilization of the proximal trachea.
Collapse
Affiliation(s)
- Yusuke Takanashi
- Department of Surgery 1, Hamamatsu University School of Medicine, Hamamatsu, Japan.,Department of Thoracic Surgery, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Hiroshi Neyatani
- Department of Thoracic Surgery, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Kazuhito Funai
- Department of Surgery 1, Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
29
|
Matsuura S, Yamashita H, Kinateder KKJ. A statistical test for the hypothesis of Gaussian random function. STATISTICS-ABINGDON 2018. [DOI: 10.1080/02331888.2018.1435659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Shun Matsuura
- Faculty of Science and Technology, Keio University, Yokohama, Japan
| | - Haruka Yamashita
- Faculty of Science and Technology, Sophia University, Tokyo, Japan
| | | |
Collapse
|
30
|
Fujita H, Sasaki T, Miyamoto T, Mori T, Nakabayashi K, Hata K, Matsuura S, Matsubara Y, Amagai M, Kubo A. 733 Identification and molecular characterization of a CDC20 mutation in a novel mosaic variegated aneuploidy syndrome with premature aging phenotypes. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
31
|
Mochizuki E, Matsuura S, Oishi K, Miyashita K, Ichijyo K, Furukawa S, Nagaoka M, Mikura S, Tsukui M, Koshimizu N, Sakurai S, Asada K, Shirai T. Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung. World J Surg Oncol 2018; 16:33. [PMID: 29454358 PMCID: PMC5816519 DOI: 10.1186/s12957-018-1337-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 02/07/2018] [Indexed: 12/25/2022] Open
Abstract
Background There are few reports about the factor influencing the prognosis of high-grade neuroendocrine carcinoma. In this study, we evaluated surgical outcome of clinical stage I high-grade neuroendocrine carcinoma. Methods Patients who underwent curative surgery for high-grade neuroendocrine tumors of the lung in clinical stage I were included in this study. We retrospectively analyzed 27 consecutive patients. The aim of this study was to clarify the clinical course of the disease after surgery and what factors influence the prognosis. Results Twenty-two patients have small cell carcinoma, and 5 patients have large cell neuroendocrine carcinoma. Patients who could undergo surgery within 60 days after the first visit (p < 0.01) and undergo lobectomy (p < 0.01) and whose pro-gastrin-releasing peptide ≦ 72 pg/ml (p = 0.04) performed good prognosis after surgery. In multivariate analysis, surgery within 60 days and operative procedure were independent factors associated with OS. Conclusion Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung should be performed as early as possible, and better outcome can be obtained with lobectomy than partial resection.
Collapse
Affiliation(s)
- Eisuke Mochizuki
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan.
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Kyohei Oishi
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Koichi Miyashita
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Koshiro Ichijyo
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Syunya Furukawa
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Miyuki Nagaoka
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Shinichiro Mikura
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Masaru Tsukui
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Naoki Koshimizu
- Department of Respiratory Medicine, Fujieda Municipal Hospital, 4-1-11 Surugadai, Fujieda, Shizuoka, 426-8677, Japan
| | - Shogo Sakurai
- Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-Ando, Aoi, Shizuoka, 420-8527, Japan
| | - Kazuhiro Asada
- Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-Ando, Aoi, Shizuoka, 420-8527, Japan
| | - Toshihiro Shirai
- Department of Respiratory Medicine, Shizuoka General Hospital, 4-27-1 Kita-Ando, Aoi, Shizuoka, 420-8527, Japan
| |
Collapse
|
32
|
Matsuura S. Correlation coefficient of response variances in compound noise and product array experiments. COMMUN STAT-THEOR M 2018. [DOI: 10.1080/03610926.2017.1313985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Shun Matsuura
- Department of Administration Engineering, Faculty of Science and Technology, Keio University, Yokohama, Japan
| |
Collapse
|
33
|
Miyashita K, Matsuura S, Naoi H, Tsukui M, Koshimizu N, Suda T. Successful treatment by tolvaptan of the syndrome of inappropriate antidiuretic hormone secretion that may be associated with chemotherapy-induced tumour lysis in a patient with small-cell lung carcinoma. Respirol Case Rep 2018; 6:e00296. [PMID: 29796276 PMCID: PMC5961507 DOI: 10.1002/rcr2.296] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Revised: 12/05/2017] [Accepted: 12/14/2017] [Indexed: 11/25/2022] Open
Abstract
Here, we report the case of a patient with small‐cell lung carcinoma (SCLC) who developed the syndrome of inappropriate antidiuretic hormone secretion (SIADH). This syndrome may be associated with chemotherapy‐induced tumour lysis. Our patient was successfully treated with tolvaptan. A 70‐year‐old man was diagnosed with SCLC and was treated with carboplatin and etoposide. Episodes of hyponatremia occurred after every four cycles of chemotherapy that achieved tumour reduction; however, the hyponatremia was improved by temporary administration of tolvaptan. In SIADH associated with chemotherapy‐induced tumour lysis, tolvaptan may improve hyponatremia and enable the continued administration of effective chemotherapy.
Collapse
Affiliation(s)
- Koichi Miyashita
- Department of Respiratory Medicine Fujieda Municipal General Hospital Fujieda Japan
| | - Shun Matsuura
- Department of Respiratory Medicine Fujieda Municipal General Hospital Fujieda Japan
| | - Hyogo Naoi
- Department of Respiratory Medicine Fujieda Municipal General Hospital Fujieda Japan
| | - Masaru Tsukui
- Department of Respiratory Medicine Fujieda Municipal General Hospital Fujieda Japan
| | - Naoki Koshimizu
- Department of Respiratory Medicine Fujieda Municipal General Hospital Fujieda Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
| |
Collapse
|
34
|
Matsuura S, Mochizuka Y, Oishi K, Miyashita K, Naoi H, Mochizuki E, Mikura S, Tsukui M, Koshimizu N, Ohata A, Suda T. Sarcoidosis with Pancreatic Mass, Endobronchial Nodules, and Miliary Opacities in the Lung. Intern Med 2017; 56:3083-3087. [PMID: 28943576 PMCID: PMC5725865 DOI: 10.2169/internalmedicine.8916-17] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Sarcoidosis affects multiple organs and rarely has unusual manifestations. A 78-year-old woman was referred to our hospital for coughing symptoms. A chest computed tomography (CT) scan revealed bilateral diffuse miliary patterns and right pleural effusion. Bronchoscopy showed multiple nodules in the carina and the bronchus intermedius. A CT scan of her abdomen revealed hypovascular lesions involving the pancreatic head and body. A transbronchial lung biopsy, bronchial mucosal biopsy, and endoscopic ultrasound-guided fine-needle aspiration of the pancreatic mass demonstrated non-caseating granulomas. We diagnosed the patient with sarcoidosis. She received no treatment for sarcoidosis and has been followed up for one year, during which no pulmonary disease progression had been observed and the pancreatic masses partially regressed.
Collapse
Affiliation(s)
- Shun Matsuura
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Yasutaka Mochizuka
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Kyohei Oishi
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Koichi Miyashita
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Hyogo Naoi
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Eisuke Mochizuki
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Shinichiro Mikura
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Masaru Tsukui
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Naoki Koshimizu
- Division of Respiratory Internal Medicine, Fujieda Municipal General Hospital, Japan
| | - Akihiko Ohata
- Division of Gastroenterology, Fujieda Municipal General Hospital, Japan
| | - Takahumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Japan
| |
Collapse
|
35
|
Inoue Y, Matsuura S, Yoshimura K, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Maeda M, Ogawa H, Inui N, Funai K, Shinmura K, Niwa H, Suda T, Sugimura H. Characterization of V-set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells. Cancer Sci 2017; 108:1701-1714. [PMID: 28603843 PMCID: PMC5543479 DOI: 10.1111/cas.13295] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Revised: 05/31/2017] [Accepted: 06/05/2017] [Indexed: 12/30/2022] Open
Abstract
V‐set and immunoglobulin domain containing 1 (VSIG1) is a newly discovered member of the immunoglobulin superfamily of proteins, expressed in normal stomach and testis. In cancers, however, the clinical and biological roles of VSIG1 remain unknown. Here we investigated VSIG1 expression in 11 cancers and assessed the prognostic roles of VSIG1 in patients with gastric cancer (GC) (n = 362) and non‐small‐cell lung cancer (n = 650). V‐set and immunoglobulin domain containing 1 was downregulated in 60.5% of GC specimens, and high VSIG1 expression was identified as an independent favorable prognostic factor for overall survival in GC patients (hazard ratio, 0.58; 95% confidence interval, 0.35–0.96). Among lung adenocarcinomas (n = 428), VSIG1 was significantly and inversely associated with thyroid transcription factor 1 expression and was frequently expressed in the invasive mucinous subtype (17 of 19, 89.5%). In addition, VSIG1 was expressed in a subset of pancreatic, ovarian, and prostate cancers. The variant 2 VSIG1 transcript was the dominant form in these tissues and cancer cells. Introduction of VSIG1 significantly reduced the proliferative ability of MKN1 and MKN28 GC cells and H1299 lung cancer cells and downregulated cell migration of these cells, as well as of KYSE150, an esophageal cancer cell line. Cell invasion of MKN1, MKN28, and KYSE150 cells was also reduced by VSIG1 introduction. In vitro characterization revealed that VSIG1 forms homodimers through homophilic cis‐interactions but not through homophilic trans‐interactions. These results suggest that VSIG1 possesses tumor suppressive functions that are translated into favorable prognosis of VSIG1‐expressing GC patients.
Collapse
Affiliation(s)
- Yusuke Inoue
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.,Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Shun Matsuura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.,Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.,Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan
| | - Katsuhiro Yoshimura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.,Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yuji Iwashita
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Tomoaki Kahyo
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Akikazu Kawase
- First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Masayuki Tanahashi
- Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Matsuyoshi Maeda
- Department of Pathology, Toyohashi Municipal Hospital, Toyohashi, Japan
| | - Hiroshi Ogawa
- Department of Pathology, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Naoki Inui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.,Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kazuhito Funai
- First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kazuya Shinmura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hiroshi Niwa
- Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Haruhiko Sugimura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
36
|
Grosso J, Inagaki A, Collins S, Matsuura S, Kamath P, Ince T, Kasahara N, Slomovitz B. Pseudotyped retroviral replicating vectors for combination prodrug activator gene therapy of ovarian cancer. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Collins S, Inagaki A, Grosso J, Matsuura S, Kamath P, Xu X, Ince T, Slomovitz B, Kasahara N. Vocimagene amiretrorepvec (Toca 511) for prodrug activator gene therapy in ovarian cancer models. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
38
|
Yamashita H, Matsuura S, Suzuki H. Estimation of principal points for a multivariate binary distribution using a log-linear model. COMMUN STAT-SIMUL C 2017. [DOI: 10.1080/03610918.2014.992541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Haruka Yamashita
- Graduate School of Science and Technology, Keio University, Yokohama, Kanagawa, Japan
- The Japan Society for the Promotion of Science, Hiyoshi, Kohoku-ku, Yokohama, Kanagawa, Japan
| | - Shun Matsuura
- The Japan Society for the Promotion of Science, Hiyoshi, Kohoku-ku, Yokohama, Kanagawa, Japan
- Faculty of Science and Technology, Keio University, Yokohama, Kanagawa, Japan
| | - Hideo Suzuki
- The Japan Society for the Promotion of Science, Hiyoshi, Kohoku-ku, Yokohama, Kanagawa, Japan
- Faculty of Science and Technology, Keio University, Yokohama, Kanagawa, Japan
| |
Collapse
|
39
|
Leiva O, Ng SK, Chitalia S, Balduini A, Matsuura S, Ravid K. The role of the extracellular matrix in primary myelofibrosis. Blood Cancer J 2017; 7:e525. [PMID: 28157219 PMCID: PMC5386340 DOI: 10.1038/bcj.2017.6] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 12/20/2016] [Indexed: 02/06/2023] Open
Abstract
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that arises from clonal proliferation of hematopoietic stem cells and leads to progressive bone marrow (BM) fibrosis. While cellular mutations involved in the development of PMF have been heavily investigated, noteworthy is the important role the extracellular matrix (ECM) plays in the progression of BM fibrosis. This review surveys ECM proteins contributors of PMF, and highlights how better understanding of the control of the ECM within the BM niche may lead to combined therapeutic options in PMF.
Collapse
Affiliation(s)
- O Leiva
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - S K Ng
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - S Chitalia
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - A Balduini
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.,Laboratory of Biotechnology, IRCCS San Matteo Foundation, Pavia, Italy
| | - S Matsuura
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - K Ravid
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| |
Collapse
|
40
|
Matsunaga K, Takanashi Y, Oiki H, Hayakawa T, Matsuura S, Neyatani H. [Endobronchial Hamartoma Requiring Lobectomy;Report of a Case]. Kyobu Geka 2016; 69:1115-1118. [PMID: 27909283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
We present a rare case of endobronchial hamartoma that required right middle and lower lobectomy. A 59-year-old man presented with cough and sputum lasting for 9 months. Chest X-ray revealed obstructive pneumonia of the right inferior lobe. Chest computed tomography demonstrated an intrabronchial mass lesion, size 12×12 mm, occluding the entrance of the right lower lobe bronchus associated with obstructive pneumonia of the right inferior lobe. Because transbronchial biopsy could not confirm the diagnosis, we performed a right middle and lower lobectomy to diagnose and treat obstructive pneumonia. Histopathological diagnosis of the tumor was hamartoma. Hamartoma, the most common benign lung tumor, is classified into the following 2 types:pulmonary parenchyma and endobronchial, the latter is relatively rare. Although hamartomas have benign characteristics, cases of endobronchial hamartomas associated with obstructive pneumonia may require lobectomy.
Collapse
Affiliation(s)
- Kyosuke Matsunaga
- Departments of Thoracic Surgery, Fujieda Municipal General Hospital, Fujieda, Japan
| | | | | | | | | | | |
Collapse
|
41
|
Affiliation(s)
- S Matsuura
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - S Patterson
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - H Lucero
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - O Leiva
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - A K Grant
- Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
| | - V L M Herrera
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
| | - K Ravid
- Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
- Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
| |
Collapse
|
42
|
Weng S, Matsuura S, Mowery CT, Stoner SA, Lam K, Ran D, Davis AG, Lo MC, Zhang DE. Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity. Leukemia 2016; 31:159-169. [PMID: 27389055 PMCID: PMC5214981 DOI: 10.1038/leu.2016.167] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Revised: 05/19/2016] [Accepted: 05/23/2016] [Indexed: 02/06/2023]
Abstract
GM-CSF signaling regulates hematopoiesis and immune responses. CSF2RA, the gene encoding the α subunit for GM-CSF, is significantly downregulated in t(8;21) (RUNX1-ETO or RE) leukemia patients, suggesting that it may serve as a tumor suppressor. We previously reported that GM-CSF signaling is inhibitory to RE leukemogenesis. Here we conducted gene expression profiling of primary RE hematopoietic stem/progenitor cells (HSPCs) treated with GM-CSF to elucidate the mechanisms mediating the negative effects of GM on RE leukemogenicity. We observed that GM treatment of RE HSPCs resulted in a unique gene expression profile that resembles primary human cells undergoing myelopoiesis, which was not observed in control HSPCs. Additionally we discovered that GM-CSF signaling attenuates MYC-associated gene signatures in RE HSPCs. In agreement with this, a functional screen of a subset of GM-CSF-responsive genes demonstrated that a MYC inhibitor, MXI1, reduced the leukemic potential of RE HSPCs and t(8;21) AML cells. Furthermore, MYC knockdown and treatment with the BET inhibitor JQ1 reduced the leukemic potential of t(8;21) cell lines. Altogether, we discovered a novel molecular mechanism mediating the GM-CSF-induced reduction in leukemic potential of RE cells, and our findings support MYC inhibition as an effective strategy for reducing the leukemogenicity of t(8;21) AML.
Collapse
Affiliation(s)
- S Weng
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - S Matsuura
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - C T Mowery
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - S A Stoner
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - K Lam
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - D Ran
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - A G Davis
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - M-C Lo
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - D-E Zhang
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.,Department of Pathology and Division of Biological Sciences, University of California San Diego, La Jolla, CA, USA
| |
Collapse
|
43
|
Matsuura S, Royba E, Akutsu SN, Yanagihara H, Ochiai H, Kudo Y, Tashiro S, Miyamoto T. Analysis of individual differences in radiosensitivity using genome editing. Ann ICRP 2016; 45:290-6. [PMID: 27012844 DOI: 10.1177/0146645316633941] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Current standards for radiological protection of the public have been uniformly established. However, individual differences in radiosensitivity are suggested to exist in human populations, which could be caused by nucleotide variants of DNA repair genes. In order to verify if such genetic variants are responsible for individual differences in radiosensitivity, they could be introduced into cultured human cells for evaluation. This strategy would make it possible to analyse the effect of candidate nucleotide variants on individual radiosensitivity, independent of the diverse genetic background. However, efficient gene targeting in cultured human cells is difficult due to the low frequency of homologous recombination (HR) repair. The development of artificial nucleases has enabled efficient HR-mediated genome editing to be performed in cultured human cells. A novel genome editing strategy, 'transcription activator-like effector nuclease (TALEN)-mediated two-step single base pair editing', has been developed, and this was used to introduce a nucleotide variant associated with a chromosomal instability syndrome bi-allelically into cultured human cells to demonstrate that it is the causative mutation. It is proposed that this editing technique will be useful to investigate individual radiosensitivity.
Collapse
Affiliation(s)
- S Matsuura
- Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan
| | - E Royba
- Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan
| | - S N Akutsu
- Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan
| | - H Yanagihara
- Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan
| | - H Ochiai
- Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Japan
| | - Y Kudo
- Department of Obstetrics and Gynaecology, Graduate School of Biomedical Sciences, Hiroshima University, Japan
| | - S Tashiro
- Department of Cellular Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
| | - T Miyamoto
- Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan
| |
Collapse
|
44
|
|
45
|
Inoue Y, Kurabe N, Matsuura S, Maeda M, Kahyo T, Igarashi H, Funai K, Niwa H, Ogawa H, Shinmura K, Konno H, Suda T, Sugimura H. Abstract 519: V-set and immunoglobulin domain containing 1 (VSIG1) demonstrates a tumor suppressive function in gastric cancer and non-small cell lung cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
V-set and immunoglobulin domain containing 1 (VSIG1) was recently identified as a novel member of immunoglobulin-like cell-adhesion molecules. In human, VSIG1 has 2 transcript variant forms (variant 1 and variant 2). In normal tissues, VSIG1 was reported to be expressed predominantly in stomach and testis. In cancerous tissues, the expression of VSIG1 was shown to be restricted in a part of gastric, esophageal, and ovarian cancers. However, the role of VSIG1 in cancer progression has not been elucidated.
VSIG1 protein expression in human normal tissues obtained at autopsy was detected by western blot analysis. We also analyzed VSIG1 protein expression in 8 non-small cell lung cancer (NSCLC) cell lines and 8 gastric cancer (GC) cell lines by western blot. Relative mRNA expression was evaluated by quantitative real-time PCR in patients with resected NSCLC (n = 69). Protein expression in NSCLC (n = 277) and GC (n = 362) were analyzed using immunohistochemistry. The effects of VSIG1 in proliferation, migration, and invasion were assessed in NSCLC and GC cell lines by ectopic expression of a human full-length VSIG1 variant 2 cDNA or application of specific VSIG1 siRNA.
In normal tissues of 15 organs (brain, heart, lung, esophagus, stomach, intestine, colon, rectum, liver, spleen, pancreas, adrenal gland, kidney, testis, and ovary), VSIG1 protein expression was detected in only stomach and testis, and variant 2 mRNA expression level was significantly higher than variant 1 in both stomach and testis (p<0.00001). VSIG1 mRNA was overexpressed in 21 NSCLC patients (30.4% of patients), in whom variant 2 mRNA expression level was higher than variant 1 in 15 patients (71.4%). VSIG1 protein expression was detected in 7.2% of NSCLC and 39.5% of GC. In NSCLC, VSIG1 protein expression was restricted in adenocarcinoma histology (p = 0.0002) and was negatively correlated with TTF-1 protein expression (p = 0.002). In GC, patients with VSIG1 decreased expression tumors had a worse overall rate of survival than those with expressing tumors (p = 0.014, log-rank test). In NSCLC, however, VSIG1 protein expression level did not have significant prognostic impact. In 16 NSCLC and GC cell lines, VSIG1 protein expression was detected in only MKN45 cells. Overexpression of VSIG1 significantly reduced proliferation and migration in H1299, MKN1, and MKN28 cells, and also inhibited invasion in MKN1 and MKN28 cells. On the other hand, VSIG1 downregulation enhanced proliferation in MKN45 cells.
From these findings, we conclude that VSIG1 has a tumor suppressive function which contributes to a less proliferative and invasive phenotype in cancer cells. We are exploring to identify the binding partners of VSIG1 using LC-MS/MS analysis. The results will be shown and discussed.
Citation Format: Yusuke Inoue, Nobuya Kurabe, Shun Matsuura, Matsuyoshi Maeda, Tomoaki Kahyo, Hisaki Igarashi, Kazuhito Funai, Hiroshi Niwa, Hiroshi Ogawa, Kazuya Shinmura, Hiroyuki Konno, Takafumi Suda, Haruhiko Sugimura. V-set and immunoglobulin domain containing 1 (VSIG1) demonstrates a tumor suppressive function in gastric cancer and non-small cell lung cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 519. doi:10.1158/1538-7445.AM2015-519
Collapse
Affiliation(s)
- Yusuke Inoue
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Nobuya Kurabe
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Shun Matsuura
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | | | - Tomoaki Kahyo
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | | | - Kazuhito Funai
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hiroshi Niwa
- 3Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | - Hiroshi Ogawa
- 3Seirei Mikatahara General Hospital, Hamamatsu, Japan
| | | | - Hiroyuki Konno
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Takafumi Suda
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | | |
Collapse
|
46
|
Takanashi Y, Tajima S, Matsuura S, Koyama S, Takahashi T, Neyatani H. ALK-rearranged squamous cell carcinoma of the lung. Respirol Case Rep 2015; 3:105-7. [PMID: 26392858 PMCID: PMC4571740 DOI: 10.1002/rcr2.115] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Revised: 05/14/2015] [Accepted: 05/18/2015] [Indexed: 12/12/2022] Open
Abstract
The fusion gene echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) is identified in approximately 5% of non-small-cell lung cancer patients. A rare case of ALK-positive squamous cell carcinoma of the lung is reported. A 60-year-old man, an ex-smoker with a 720-packs-per-year tobacco smoking history, presented with a mass lesion in the upper lobe of the left lung on chest computed tomography. Transbronchial biopsy of the mass confirmed a diagnosis of lung squamous cell carcinoma, and it was proven to have ALK rearrangement by fluorescent in situ hybridization. The patient underwent left upper lobectomy. Hematoxylin and eosin staining of the surgical specimen demonstrated the typical morphology of pure squamous cell carcinoma. The patient has been advised to attend regular check-ups for postoperative recurrence. ALK testing and subsequent ALK-targeted treatment can be a possible option in cases of postoperative recurrence.
Collapse
Affiliation(s)
- Yusuke Takanashi
- Department of Thoracic Surgery, Fujieda Municipal General Hospital Fujieda, Shizuoka, Japan
| | - Shogo Tajima
- Department of Pathology, Graduate School of Medicine, University of Tokyo Tokyo, Japan
| | - Shun Matsuura
- Department of Respiratory Medicine, Fujieda Municipal General Hospital Fujieda, Shizuoka, Japan
| | - Shin Koyama
- Department of Thoracic Surgery, Fujieda Municipal General Hospital Fujieda, Shizuoka, Japan
| | - Tsuyoshi Takahashi
- Department of Thoracic Surgery, Fujieda Municipal General Hospital Fujieda, Shizuoka, Japan
| | - Hiroshi Neyatani
- Department of Thoracic Surgery, Fujieda Municipal General Hospital Fujieda, Shizuoka, Japan
| |
Collapse
|
47
|
Matsuura S. Effectiveness of a random compound noise strategy for robust parameter design. J Appl Stat 2014. [DOI: 10.1080/02664763.2014.898130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
48
|
Matsuura S, Ishikura S. Suppression of Tomato mosaic virus
disease in tomato plants by deep ultraviolet irradiation using light-emitting diodes. Lett Appl Microbiol 2014; 59:457-63. [DOI: 10.1111/lam.12301] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Revised: 06/12/2014] [Accepted: 06/24/2014] [Indexed: 11/30/2022]
Affiliation(s)
- S. Matsuura
- Agriculture Research Center; Hiroshima Prefectural Technology Research Institute; Hiroshima Japan
| | - S. Ishikura
- Agriculture Research Center; Hiroshima Prefectural Technology Research Institute; Hiroshima Japan
| |
Collapse
|
49
|
Harada M, Kotake Y, Ohhata T, Kitagawa K, Niida H, Matsuura S, Funai K, Sugimura H, Suda T, Kitagawa M. YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers. Genes Cells 2014; 19:504-16. [PMID: 24774443 DOI: 10.1111/gtc.12150] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Accepted: 03/07/2014] [Indexed: 12/27/2022]
Abstract
Cyclin D1, an oncogenic G1 cyclin, and YB-1, a transcription factor involved in cell growth, are both over-expressed in several human cancers. In human lung cancer, the functional association between YB-1 and cyclin D1 has never been elucidated. In this study, we show YB-1 is involved in the transcription of cyclin D1 in human lung cancer. Depletion of endogenous YB-1 by siRNA inhibited progression of G1 phase and down-regulated both the protein and mRNA levels of cyclin D1 in human lung cancer cells. Forced over-expression of YB-1 with a cyclin D1 reporter plasmid increased luciferase activity, and ChIP assay results showed YB-1 bound to the cyclin D1 promoter. Moreover, the amount of YB-1 mRNA positively correlated with cyclin D1 mRNA levels in clinical non-small-cell lung cancer (NSCLC) specimens. Immunohistochemical analysis also indicated YB-1 expression correlated with cyclin D1 expression in NSCLC specimens. In addition, most of the cases expressing both cyclin D1 and CDC6, another molecule controlled by YB-1, had co-existing YB-1 over-expression. Together, our results suggest that aberrant expression of both cyclin D1 and CDC6 by YB-1 over-expression may collaboratively participate in lung carcinogenesis.
Collapse
Affiliation(s)
- Masanori Harada
- Department of Molecular Biology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan; Second Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Shinmura K, Kato H, Matsuura S, Inoue Y, Igarashi H, Nagura K, Nakamura S, Maruyama K, Tajima M, Funai K, Ogawa H, Tanahashi M, Niwa H, Sugimura H. A novel somatic FGFR3 mutation in primary lung cancer. Oncol Rep 2014; 31:1219-24. [PMID: 24452392 DOI: 10.3892/or.2014.2984] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Accepted: 11/25/2013] [Indexed: 11/05/2022] Open
Abstract
The recent discovery of mutations and fusions of oncokinase genes in a subset of lung cancers (LCs) is of considerable clinical interest, since LCs containing such mutations or fusion transcripts are reportedly sensitive to kinase inhibitors. To better understand the role of the recently identified fibroblast growth factor receptor 3 (FGFR3) mutations and fusions in pulmonary carcinogenesis, we examined 214 LCs for mutations in the mutation cluster region of the FGFR3 gene using sequencing analysis. We also examined 190 LCs for the FGFR3-TACC3 and FGFR3-BAIAP2L1 fusion transcripts using reverse transcription-polymerase chain reaction (RT-PCR) analysis. Although the expression of FGFR3-TACC3 and FGFR3-BAIAP2L1 fusion transcripts was not detected in any of the carcinomas, somatic FGFR3 mutations were detected in two (0.9%) LCs. The two mutations were the same, i.e., p.R248H. That was a novel mutation occurring in the same codon as p.R248C, for which an oncogenic potential has previously been shown. Increased FGFR3 expression was shown in the two LCs containing the FGFR3 p.R248H mutation using qPCR. Histologically, both carcinomas were squamous cell carcinomas, therefore the incidence of the FGFR3 mutation among the squamous cell carcinoma cases was calculated as 3.2% (2/63). When we examined other co-occurring genetic abnormalities, one case exhibited a p53 p.R273C mutation, while the other case exhibited PIK3CA and SOX2 amplifications. The above results suggest that an FGFR3 p.R248H mutation is involved in the carcinogenesis of a subset of LCs and may contribute to the elucidation of the characteristics of FGFR3 mutation-positive LCs in the future.
Collapse
Affiliation(s)
- Kazuya Shinmura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Hisami Kato
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Shun Matsuura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Yusuke Inoue
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Hisaki Igarashi
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Kiyoko Nagura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Satoki Nakamura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Kyoko Maruyama
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Mari Tajima
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Kazuhito Funai
- Department of Surgery 1, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| | - Hiroshi Ogawa
- Division of Pathology, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka 433-8558, Japan
| | - Masayuki Tanahashi
- Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka 433-8558, Japan
| | - Hiroshi Niwa
- Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka 433-8558, Japan
| | - Haruhiko Sugimura
- Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
| |
Collapse
|